We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
-3.06%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$77.7B
AUM Growth
-$3.9B
(-4.8%)
Cap. Flow
+$505M
Cap. Flow
% of AUM
0.65%
Top 10 Holdings %
Top 10 Hldgs %
24.09%
Holding
3,066
New
55
Increased
1,481
Reduced
1,461
Closed
51
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$83.5M |
| 2 |
S&P Global
SPGI
|
+$73.5M |
| 3 |
Tesla
TSLA
|
+$55.8M |
| 4 |
Microsoft
MSFT
|
+$45.9M |
| 5 |
Amazon
AMZN
|
+$27.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
XLNX
Xilinx Inc
XLNX
|
+$88.8M |
| 2 |
INFO
IHS Markit Ltd. Common Shares
INFO
|
+$74.7M |
| 3 |
CONE
CyrusOne Inc Common Stock
CONE
|
+$31.7M |
| 4 |
Abbott
ABT
|
+$25.5M |
| 5 |
Exelon
EXC
|
+$23.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.74% |
| 2 | Financials | 13.53% |
| 3 | Healthcare | 13.01% |
| 4 | Consumer Discretionary | 11.66% |
| 5 | Industrials | 8.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VIRX
2776
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $184K | ﹤0.01% |
38,693
+3,497
| +10% | +$10.5K |
|
|
FUV
2777
DELISTED
Arcimoto, Inc. Common Stock
FUV
| $184K | ﹤0.01% |
1,390
+81
| +6% | +$10.5K |
|
2778
Alta Equipment Group
ALTG
$245M
| $183K | ﹤0.01% |
14,820
-2,400
| -14% | -$31.6K |
|
|
AMTI
2779
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
| $183K | ﹤0.01% |
24,335
+1,517
| +7% | +$12.6K |
|
2780
Ginkgo Bioworks
DNA
$521M
| $182K | ﹤0.01% |
1,130
| – | – |
|
2781
CytomX Therapeutics
CTMX
$754M
| $180K | ﹤0.01% |
67,376
+428
| +0.6% | +$1.64K |
|
|
VLDR
2782
DELISTED
Velodyne Lidar, Inc. Common Stock
VLDR
| $179K | ﹤0.01% |
69,797
+7,049
| +11% | +$24.1K |
|
2783
Apyx Medical
APYX
$171M
| $178K | ﹤0.01% |
27,228
+3,769
| +16% | +$37.1K |
|
2784
Atossa Therapeutics
ATOS
$23.5M
| $177K | ﹤0.01% |
9,460
+685
| +8% | +$13.9K |
|
2785
Escalade
ESCA
$311M
| $177K | ﹤0.01% |
13,425
-1,235
| -8% | -$17.4K |
|
|
IMA
2786
ImageneBio Inc
IMA
$64.6M
| $175K | ﹤0.01% |
2,397
+55
| +2% | +$5.85K |
|
2787
Spruce Power Holding Corp
SPRU
$39.9M
| $175K | ﹤0.01% |
10,965
+5,778
| +111% | +$101K |
|
|
LTRPA
2788
DELISTED
Liberty TripAdvisor Holdings, Inc. Series A
LTRPA
| $175K | ﹤0.01% |
85,498
-2,655
| -3% | -$5.63K |
|
2789
Telesat
TSAT
$897M
| $172K | ﹤0.01% |
10,429
-3,767
| -27% | -$83.9K |
|
2790
Q32 Bio
QTTB
$464M
| $172K | ﹤0.01% |
3,151
-190
| -6% | -$11.8K |
|
|
PZN
2791
DELISTED
Pzena Investment Management, Inc. Class A
PZN
| $168K | ﹤0.01% |
20,900
+11
| +0.1% | +$100 |
|
2792
Eos Energy Enterprises
EOSE
$1.51B
| $167K | ﹤0.01% |
39,877
+6,423
| +19% | +$26.5K |
|
2793
Lexicon Pharmaceuticals
LXRX
$1.1B
| $167K | ﹤0.01% |
79,934
-6,726
| -8% | -$18.6K |
|
2794
NN Inc
NNBR
$311M
| $167K | ﹤0.01% |
57,949
-4,913
| -8% | -$16.2K |
|
|
RMO
2795
DELISTED
Romeo Power, Inc.
RMO
| $166K | ﹤0.01% |
111,497
+3,042
| +3% | +$6.4K |
|
2796
Outlook Therapeutics
OTLK
$191M
| $165K | ﹤0.01% |
4,632
+2,235
| +93% | +$69.8K |
|
2797
Park-Ohio Holdings
PKOH
$761M
| $164K | ﹤0.01% |
11,653
-1,044
| -8% | -$18.9K |
|
2798
Mistras Group
MG
$512M
| $163K | ﹤0.01% |
24,678
-2,790
| -10% | -$19K |
|
2799
Zevra Therapeutics
ZVRA
$686M
| $163K | ﹤0.01% |
32,381
-850
| -3% | -$5.41K |
|
2800
XBiotech
XBIT
$69.2M
| $162K | ﹤0.01% |
18,748
-1,962
| -9% | -$19.7K |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2022 Portfolio in Review
As of Q1 2022, RhumbLine Advisers held 3,066 positions worth $77.7B, down 4.8% from $81.6B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Trading was light in Q1 2022: portfolio turnover was 3.5%. RhumbLine Advisers opened 55 new positions and exited 51, leaving the 3,066-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 25% of assets, down from 26% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q1 2022 buy was Constellation Energy: 528,261 shares worth $29.7M.
- RhumbLine Advisers added most to Advanced Micro Devices in Q1 2022, an estimated $83.5M increase.
- RhumbLine Advisers's biggest Q1 2022 reduction was Abbott, cutting an estimated $25.5M.
- RhumbLine Advisers fully exited Xilinx Inc in Q1 2022, selling an estimated $88.8M.
- RhumbLine Advisers's ten largest holdings make up 24% of its $77.7B portfolio in Q1 2022.
- RhumbLine Advisers opened 55 new positions and closed 51 in Q1 2022.
- RhumbLine Advisers's portfolio value fell 4.8% quarter-over-quarter to $77.7B.
Based on RhumbLine Advisers's 13F filing for Q1 2022, filed 12 May 2022.